(State or Other Jurisdiction of Incorporation) | (I.R.S. Employer Identification No.) |
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Page No. | ||
Condensed Consolidated Balance Sheets — September 30, 2024 and December 31, 2023 | ||
Condensed Consolidated Statements of Operations — Three and Nine Months Ended September 30, 2024 and 2023 | ||
Condensed Consolidated Statements of Comprehensive Income (Loss) — Three and Nine Months Ended September 30, 2024 and 2023 | ||
Condensed Consolidated Statements of Stockholders’ Equity — Three and Nine Months Ended September 30, 2024 and 2023 | ||
Condensed Consolidated Statements of Cash Flows — Nine Months Ended September 30, 2024 and 2023 | ||
•our belief that our PX offers market-leading value with the highest technological and economic benefit; |
•our belief that leveraging our pressure exchanger technology will unlock new commercial opportunities in the future; |
•our belief that our PX G1300™ can contribute to help make CO2-based refrigeration economically viable in a broader range of climates; |
•our belief that our technology helps our customer achieve environmentally sustainable operations; |
•our expectation that sales outside of the U.S. will remain a significant portion of our revenue; |
•the scale of the environmental impact from the use of our solutions; |
•our belief that our sustainability goals are highly influential to our business success; |
•the timing of our receipt of payment for products or services from our customers; |
•our belief that our existing cash and cash equivalents, our short and/or long-term investments, and the ongoing cash generated from our operations, will be sufficient to meet our anticipated liquidity needs for the foreseeable future, with the exception of a decision to enter into an acquisition and/or fund investments in our latest technology arising from rapid market adoption that could require us to seek additional equity or debt financing; |
•our expectations relating to the amount and timing of recognized revenue from our projects; |
•our expectations relating to expenses; |
•our expectation that we will continue to receive a tax benefit related to U.S. federal foreign-derived intangible income and research and development tax credit; |
•the outcome of proceedings, lawsuits, disputes and claims; |
•the impact of losses due to indemnification obligations; |
•other factors disclosed under the MD&A and Part I, Item 3, “Quantitative and Qualitative Disclosures about Market Risk,” and elsewhere in this Form 10-Q. |
September 30, 2024 | December 31, 2023 | ||
(In thousands) | |||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | $ | $ | |
Short-term investments | |||
Accounts receivable, net | |||
Inventories, net | |||
Prepaid expenses and other assets | |||
Total current assets | |||
Long-term investments | |||
Deferred tax assets, net | |||
Property and equipment, net | |||
Operating lease, right of use asset | |||
Goodwill | |||
Other assets, non-current | |||
Total assets | $ | $ | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||
Current liabilities: | |||
Accounts payable | $ | $ | |
Accrued expenses and other liabilities | |||
Lease liabilities | |||
Contract liabilities | |||
Total current liabilities | |||
Lease liabilities, non-current | |||
Other liabilities, non-current | |||
Total liabilities | |||
Commitments and contingencies (Note 7) | |||
Stockholders’ equity: | |||
Common stock | |||
Additional paid-in capital | |||
Accumulated other comprehensive income (loss) | ( | ||
Treasury stock | ( | ( | |
Retained earnings | |||
Total stockholders’ equity | |||
Total liabilities and stockholders’ equity | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
(In thousands, except per share data) | |||||||
Revenue | $ | $ | $ | $ | |||
Cost of revenue | |||||||
Gross profit | |||||||
Operating expenses: | |||||||
General and administrative | |||||||
Sales and marketing | |||||||
Research and development | |||||||
Total operating expenses | |||||||
Income (loss) from operations | ( | ( | |||||
Other income (expense): | |||||||
Interest income | |||||||
Other non-operating income (expense), net | ( | ( | ( | ||||
Total other income, net | |||||||
Income (loss) before income taxes | ( | ||||||
Provision for (benefit from) income taxes | ( | ( | |||||
Net income (loss) | $ | $ | $( | $ | |||
Net income (loss) per share: | |||||||
Basic | $ | $ | $ ( | $ | |||
Diluted | $ | $ | $ ( | $ | |||
Number of shares used in per share calculations: | |||||||
Basic | |||||||
Diluted |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
(In thousands) | |||||||
Net income (loss) | $ | $ | $( | $ | |||
Other comprehensive income (loss), net of tax | |||||||
Foreign currency translation adjustments | ( | ( | ( | ||||
Unrealized gain (loss) on investments | ( | ||||||
Total other comprehensive income (loss), net of tax | ( | ||||||
Comprehensive income (loss) | $ | $ | $( | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
(In thousands, except shares) | |||||||
Common stock | |||||||
Beginning balance | $ | $ | $ | $ | |||
Issuance of common stock, net | — | — | |||||
Ending balance | |||||||
Additional paid-in capital | |||||||
Beginning balance | |||||||
Issuance of common stock, net | |||||||
Stock-based compensation | |||||||
Ending balance | |||||||
Accumulated other comprehensive income (loss) | |||||||
Beginning balance | ( | ( | ( | ( | |||
Other comprehensive income (loss) | |||||||
Foreign currency translation adjustments | ( | ( | ( | ||||
Unrealized gain (loss) on investments | ( | ||||||
Total other comprehensive income (loss), net | ( | ||||||
Ending balance | ( | ( | |||||
Treasury stock | |||||||
Beginning and ending balance | ( | ( | ( | ( | |||
Retained earnings | |||||||
Beginning balance | |||||||
Net (loss) income | ( | ||||||
Ending balance | |||||||
Total stockholders’ equity | $ | $ | $ | $ | |||
Common stock issued (shares) | |||||||
Beginning balance | |||||||
Issuance of common stock, net | |||||||
Ending balance | |||||||
Treasury stock (shares) | |||||||
Beginning and ending balance | |||||||
Total common stock outstanding (shares) |
Nine Months Ended September 30, | |||
2024 | 2023 | ||
(In thousands) | |||
Cash flows from operating activities: | |||
Net (loss) income | $( | $ | |
Adjustments to reconcile net (loss) income to cash provided by (used in) operating activities | |||
Stock-based compensation | |||
Depreciation and amortization | |||
Right of use asset amortization | |||
Accretion (amortization) of discounts (premiums) on investments | ( | ( | |
Deferred income taxes | ( | ( | |
Other non-cash adjustments | |||
Changes in operating assets and liabilities: | |||
Accounts receivable, net | |||
Contract assets | ( | ||
Inventories, net | ( | ( | |
Prepaid and other assets | ( | ( | |
Accounts payable | |||
Accrued expenses and other liabilities | ( | ( | |
Contract liabilities | |||
Net cash provided by operating activities | |||
Cash flows from investing activities: | |||
Sales of marketable securities | |||
Maturities of marketable securities | |||
Purchases of marketable securities | ( | ( | |
Capital expenditures | ( | ( | |
Proceeds from sales of fixed assets | |||
Net cash used in investing activities | ( | ( | |
Cash flows from financing activities: | |||
Net proceeds from issuance of common stock | |||
Net cash provided by financing activities | |||
Effect of exchange rate differences on cash and cash equivalents | ( | ||
Net change in cash, cash equivalents and restricted cash | ( | ( | |
Cash, cash equivalents and restricted cash, beginning of year | |||
Cash, cash equivalents and restricted cash, end of period | $ | $ | |
Three Months Ended September 30, 2024 | Nine Months Ended September 30, 2024 | ||||||||||
Water | Emerging Technologies | Total | Water | Emerging Technologies | Total | ||||||
(In thousands) | |||||||||||
Geographical market | |||||||||||
Middle East and Africa | $ | $ | $ | $ | $ | $ | |||||
Asia | |||||||||||
Americas | |||||||||||
Europe | |||||||||||
Total revenue | $ | $ | $ | $ | $ | $ | |||||
Channel | |||||||||||
Megaproject | $ | $ | $ | $ | $ | $ | |||||
Original equipment manufacturer | |||||||||||
Aftermarket | |||||||||||
Total revenue | $ | $ | $ | $ | $ | $ |
Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2023 | ||||||||||
Water | Emerging Technologies | Total | Water | Emerging Technologies | Total | ||||||
(In thousands) | |||||||||||
Geographical market | |||||||||||
Middle East and Africa | $ | $ | $ | $ | $ | $ | |||||
Asia | |||||||||||
Americas | |||||||||||
Europe | |||||||||||
Total revenue | $ | $ | $ | $ | $ | $ | |||||
Channel | |||||||||||
Megaproject | $ | $ | $ | $ | $ | $ | |||||
Original equipment manufacturer | |||||||||||
Aftermarket | |||||||||||
Total revenue | $ | $ | $ | $ | $ | $ |
September 30, 2024 | December 31, 2023 | ||
(In thousands) | |||
Accounts receivable, net | $ | $ | |
Contract assets: | |||
Contract assets, current (included in prepaid expenses and other assets) | $ | $ | |
Contract assets, non-current (included in other assets, non-current) | |||
Total contract assets | $ | $ | |
Contract liabilities: | |||
Contract liabilities, current | $ | $ | |
Contract liabilities, non-current (included in other liabilities, non-current) | |||
Total contract liabilities | $ | $ |
September 30, 2024 | December 31, 2023 | ||
(In thousands) | |||
Contract liabilities, beginning of year | $ | $ | |
Revenue recognized | ( | ( | |
Cash received, excluding amounts recognized as revenue during the period | |||
Contract liabilities, end of period | $ | $ |
Period | Remaining Performance Obligations | |
(In thousands) | ||
2024 (remaining three months) | $ | |
2025 | ||
2026 | ||
Total |